These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 16817698)

  • 1. [Cost-effectiveness analysis of the use of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic model of the CARDS study].
    Fernández de Bobadilla J; López de Sa E; Alonso Troncoso I; Moreno Gómez R; Rubio-Terrés C; Soto Alvarez J
    An Med Interna; 2006 May; 23(5):213-9. PubMed ID: 16817698
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atorvastatin: a pharmacoeconomic review of its use in the primary and secondary prevention of cardiovascular events.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2007; 25(12):1031-53. PubMed ID: 18047388
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population.
    Annemans L; Marbaix S; Webb K; Van Gaal L; Scheen A
    Clin Drug Investig; 2010; 30(2):133-42. PubMed ID: 20067331
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes.
    Ramsey SD; Clarke LD; Roberts CS; Sullivan SD; Johnson SJ; Liu LZ
    Pharmacoeconomics; 2008; 26(4):329-39. PubMed ID: 18370567
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of statins in the prevention of coronary heart disease events in middle-aged Finnish men.
    Peura P; Martikainen J; Soini E; Hallinen T; Niskanen L
    Curr Med Res Opin; 2008 Jun; 24(6):1823-32. PubMed ID: 18485270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS.
    Lafuma A; Colin X; Solesse A
    Arch Cardiovasc Dis; 2008 May; 101(5):327-32. PubMed ID: 18656091
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness of intensive lipid lowering therapy with 80 mg of atorvastatin, versus 10 mg of atorvastatin, for secondary prevention of cardiovascular disease in Canada.
    Wagner M; Goetghebeur M; Merikle E; Pandya A; Chu P; Taylor DC
    Can J Clin Pharmacol; 2009; 16(2):e331-45. PubMed ID: 19531812
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of cost-effectiveness of simvastatin versus atorvastatin in the secondary prevention of cardiovascular events within the Brazilian public healthcare system].
    Araujo DV; Ribeiro de Souza CP; Bahia LR; Rey HC; Dos Santos Junior B; Tura BR; Berwanger O; Buehler AM; Silva MT
    Value Health; 2011; 14(5 Suppl 1):S29-32. PubMed ID: 21839894
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The lifetime cost effectiveness of amlodipine-based therapy plus atorvastatin compared with atenolol plus atorvastatin, amlodipine-based therapy alone and atenolol-based therapy alone: results from ASCOT1.
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Pharmacoeconomics; 2009; 27(3):221-30. PubMed ID: 19354342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The value of atorvastatin over the product life cycle in the United States.
    Grabner M; Johnson W; Abdulhalim AM; Kuznik A; Mullins CD
    Clin Ther; 2011 Oct; 33(10):1433-43. PubMed ID: 21955936
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacoeconomic evaluation of the effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes.
    Schwartz GG; Ganz P; Waters D; Arikian S
    Am J Cardiol; 2003 Nov; 92(9):1109-12. PubMed ID: 14583367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS).
    Raikou M; McGuire A; Colhoun HM; Betteridge DJ; Durrington PN; Hitman GA; Neil HA; Livingstone SJ; Charlton-Menys V; Fuller JH;
    Diabetologia; 2007 Apr; 50(4):733-40. PubMed ID: 17265034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Cost-effectiveness analysis of using high doses of atorvastatin for the secondary stroke prevention in Spain].
    Arrospide A; Mar J; Vivancos-Mora J; Rejas-Gutiérrez J; Caro J
    Rev Neurol; 2010 Jul; 51(1):1-11. PubMed ID: 20568062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-effectiveness analysis of rosuvastatin vs generic atorvastatin in Spain.
    Barrios V; Lobos JM; Serrano A; Brosa M; Capel M; Alvarez Sanz C
    J Med Econ; 2012; 15 Suppl 1():45-54. PubMed ID: 22954062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Results of a Markov model analysis to assess the cost-effectiveness of a single tablet of fixed-dose amlodipine and atorvastatin for the primary prevention of cardiovascular disease in Korea.
    Liew D; Park HJ; Ko SK
    Clin Ther; 2009 Oct; 31(10):2189-203; discussion 2150-1. PubMed ID: 19922890
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost effectiveness of targeted high-dose atorvastatin therapy following genotype testing in patients with acute coronary syndrome.
    Parthan A; Leahy KJ; O'Sullivan AK; Iakoubova OA; Bare LA; Devlin JJ; Weinstein MC
    Pharmacoeconomics; 2013 Jun; 31(6):519-31. PubMed ID: 23585310
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost effectiveness of HMG-CoA reductase inhibition in Canada.
    Russell MW; Huse DM; Miller JD; Kraemer DF; Hartz SC
    Can J Clin Pharmacol; 2001; 8(1):9-16. PubMed ID: 11283756
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of cholesterol-lowering therapies in Spain.
    Plans-Rubió P
    Am J Cardiovasc Drugs; 2006; 6(3):177-88. PubMed ID: 16780391
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of intensive atorvastatin treatment in high-risk patients compared with usual care in a postgeneric statin market: economic analysis of the Aggressive Lipid-lowering Initiation Abates New Cardiac Events (ALLIANCE) study.
    Mullins CD; Rattinger GB; Kuznik A; Koren MJ
    Clin Ther; 2008; 30 Pt 2():2204-16. PubMed ID: 19281915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost-effectiveness of atorvastatin for the prevention of coronary and stroke events: an economic analysis of the Anglo-Scandinavian Cardiac Outcomes Trial--lipid-lowering arm (ASCOT-LLA).
    Lindgren P; Buxton M; Kahan T; Poulter NR; Dahlöf B; Sever PS; Wedel H; Jönsson B;
    Eur J Cardiovasc Prev Rehabil; 2005 Feb; 12(1):29-36. PubMed ID: 15703503
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.